Answers are grounded in this paper and cite their sources.
Neurological complications (NC) are a known risk after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In routine clinical care, we observed unexpected severe noninfectious central nervous system (CNS) events following conditioning with fludarabine, thiotepa and melphalan (Flu-Thio-Mel). To assess the potential association between NC and Flu-Thio-Mel conditioning, we conducted a systematic retrospective evaluation of the frequency, type, location and etiology of NC in adult patients who received αβTCR+/CD19+-depleted allo-HSCT. Only NC considered conditioningrelated, based on clinical and diagnostic findings, were included. Outcomes were compared between patients receiving Flu-Thio-Mel (N=55) and patients receiving fludarabine and busulfan (Flu-Bu; N=47) as conditioning regimen for allo-HSCT. Overall, NC were frequent in both cohorts (31% after Flu-Thio-Mel and 30% after Flu-Bu) and most often clinically mild. Peripheral neuropathy was the most common manifestation. In contrast, CNS toxicity was observed exclusively in the Flu-Thio-Mel cohort (n=7), presenting as fatal leukoencephalopathy (n=3, CTCAE grade 5), severe encephalomyelopathy (n=2, CTCAE grade 3-4), and myeloneuropathy (n=2, CTCAE grade 2). Older age, impaired renal function and higher fludarabine exposure may have increased susceptibility to Flu-Thio-Mel-associated CNS toxicity. The occurrence of severe CNS toxicity (CTCAE grade 3-5) in 9% of patients after Flu-Thio-Mel warrants caution and further evaluation of this conditioning regimen, particularly in vulnerable patients.
No takes yet. Share an insight, caveat, or question.
Schonewille et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: